Taken together, our study demonstrates the antitumor activity of PRT543 in several preclinical models of ACC, providing a strong rationale for further investigation of PRMT5 inhibition as a targeted monotherapy or combination therapy for a subset of patients with ACC based on the analysis of their underlying molecular profile. Here, PRMT5 is linked to adrenal cortex carcinoma.